Patient Types

Use Blue Light Cystoscopy (BLC™) with Cysview in patients with non-muscle invasive bladder cancer. Use during the initial TURBT and in surveillance cystoscopies for intermediate and high-risk patients.

Consider for patients who:

  • Are getting their first TURBT because of suspicion of NMIBC based on a previous cystoscopy
  • Are being checked after having received BCG therapy
  • Have multiple low-grade tumors
  • Have recurrent bladder tumors
  • Are undergoing repeat resection post initial TURBT
  • Had a positive cytology and negative white light cystoscopy (WLC)

At Initial TURBT on Suspicion of NMIBC1

AUA/SUO Guideline:

In a patient with NMIBC, a clinician should offer BLC with Cysview, if available, to increase
detection and decrease recurrence. (Moderate Recommendation; Evidence Strength: Grade B)2

Following Treatment with BCG1

The decision to use BLC with Cysview in this instance should be made on a patient-by-patient basis by taking into account the benefit from accurately diagnosing more clinically significant disease cases versus the risk of false positives. The incidence of false positives decreases as time from BCG therapy increases.1

In Patents with Multiple Low-Grade Tumors1

From a prospective, comparative, within patient controlled, multicenter phase III study in the detection of Ta/T1 tumors in patients who had previously undergone a cystoscopy and had suspicion of or confirmed NMIBC.

Out of 286 patients with at least one Ta or T1 tumor, 16% were detected only with BLC with Cysview (p=0.001).3,4

In Patients with Recurrent Bladder Tumors1

A prospective, comparative, open-label, within patient controlled, multicenter phase III study in the detection of bladder cancer during surveillance.

At surveillance, 21% of recurrent patients were only found with BLC with Cysview (p<0.0001).3,5

During Re-evaluation Post Initial TURBT1

From a prospective, comparative, within patient controlled, multicenter phase III study in the detection of Ta/T1 tumors in patients
who had previously undergone a cystoscopy and had suspicion of or confirmed NMIBC.

Out of 286 patients with at least one Ta or T1 tumor, 16% were detected only with BLC with Cysview (p=0.001).3,4

In Patients with Positive Cytology and Negative White Light Cystoscopy1

AUA/SUO Guideline:

In patients with a positive cytology and negative WLC, a clinician should consider prostatic urethral biopsies and upper tract imaging, as well as enhanced cystoscopic techniques (BLC, when available), ureteroscopy, or random biopsies. (Expert Opinion).2

1 Daneshmand S, Schuckman A, Bochner B, et al. Hexaminolevulinate blue-light cystoscopy in nonmuscle-invasive bladder cancer: Review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol. 2014 Oct:11(10):589-96.

2 American Urological Association. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer. AUA/SUO Guideline 2016.

Cysview® [prescribing Information]. Photocure Inc. Princeton, NJ; 2018.

4 Stenzl A, Burger M, Fradet Y, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol. 2010;184(5):1907-13.

5 Daneshmand S et al. Efficacy and safety of blue light flexible cystoscopy With Hexaminolevulinate (HAL) in the surveillance of bladder cancer: A phase III, comparative, multi-center study. J Urol. 2017 Dec 2. pii: S0022-5347(17)78004-4. doi: 10.1016/j.juro.2017.11.096. [Epub 2017 Dec 2].